Etrasimod efficacy in patients with mildly to moderately active ulcerative colitis (modified Mayo score 4–6) in the phase 3 ELEVATE UC clinical programme
Notice bibliographique
Résumé
Introduction: Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P) 1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Objectives: To evaluate the efficacy and safety of etrasimod 2 mg QD vs placebo (PBO) in a subpopulation of patients (pts) from the ELEVATE UC clinical programme with mildly to moderately active UC at baseline (BL). Methodology: Data were pooled from the phase 3, randomised ELEVATE UC 52 (NCT03945188), ELEVATE UC 12 (NCT03996369) and ELEVATE UC 40 JAPAN (NCT04706793) trials [ 1 ] [ 2 ]. This post hoc analysis used a subset of pts aged≥18 years with a BL modified Mayo score (MMS) of 4–6 (with a centrally read endoscopic subscore≥2 and a rectal bleeding subscore [RBS]≥1). Efficacy endpoints at Week (Wk) 12 and Wk 52 included clinical remission, endoscopic improvement, symptomatic remission and endoscopic improvement-histologic remission (EIHR); at Wk 52, sustained clinical remission and corticosteroid (CS)-free clinical remission were assessed. Least square mean change from BL in pt-reported outcome 2 (PRO2) score (sum of RBS and stool frequency subscore) was assessed to Wk 52. Proportions of pts with treatment-emergent adverse events (TEAEs), serious TEAEs and TEAEs leading to discontinuation were assessed. Results: In this subgroup analysis, 221 pts received etrasimod and 109 received PBO. BL characteristics were generally balanced between treatment groups; 95 (28.8%) pts were taking CS at BL; 241 (73.0%) were biologic/Janus kinase inhibitor naïve. Median BL MMS was 6.0 in both treatment groups. Significantly greater proportions of pts receiving etrasimod vs PBO achieved all efficacy endpoints at Wk 12 and Wk 52 ([ Fig. 1 ]). A significant decrease in PRO2 score for etrasimod vs PBO was observed at Wk 2 and continued to Wk 32, with numerically greater score decreases from Wk 36 to Wk 52 ([ Table 1 ]). Safety was similar across treatment groups, and consistent with the overall ELEVATE UC population [ 1 ]. Fig. 1 Table 1 LS mean change from BL up to Wk 52 in PRO2 score in pts with mildly to moderately active UC (MMS 4–6) Pooled pt population a PBO QD, LS red (SE) [n] N=109 Etrasimod 2 mg QD, LS mean (SE) [n] N=221 LS mean difference (95% CI) p value Wk 2 -0.60 (0.134) [102] -1.06 (0.096) [212] -0.46 (-0.77, -0.15) 0.004 Wk 4 -0.89 (0.131) [104] -1.63 (0.094) [211] -0.74 (-1.04, -0.43) <0.001 Wk 8 -1.11 (0.137) [101] -1.89 (0.098) [205] -0.78 (-1.10, -0.46) <0.001 Wk 12 -1.12 (0.144) [95] -1.96 (0.102) [202] -0.84 (-1.18, -0.50) <0.001 Wk 16 -1.07 (0.216) [33] -1.90 (0.152) [101] -0.82 (-1.28, -0.37) <0.001 Wk 20 -1.07 (0.211) [34] -2.06 (0.147) [104] -0.99 (-1.43, -0.55) <0.001 Wk 24 -1.36 (0.213) [31] -1.99 (0.146) [102] -0.64 (-1.08, -0.19) 0.005 Wk 32 -1.31 (0.224) [29] -1.88 (0.148) [99] -0.57 (-1.04, -0.11) 0.017 Wk 40 -1.23 (0.265) [30] -1.71 (0.171) [95] -0.48 (-1.06, 0.09) 0.096 Wk 48 -1.30 (0.263) [27] -1.75 (0.167) [90] -0.45 (-1.02, 0.11) 0.116 Wk 52 -1.42 (0.249) [29] -1.90 (0.163) [89] -0.48 (-1.01, 0.05) 0.078 p <0.05 values are highlighted in bold. PRO2 score was defined as the sum of the RBS and SFS per individual protocol. Change from BL estimates are from an MMRM model that included BL score as a covariate and factors for study, naïve to biologic/Janus kinase inhibitor therapy at study entry (yes/no), BL CS use (yes/no), treatment, visit and the treatment by visit interaction. Data are as observed without imputation for missing values. a Data were pooled from ELEVATE UC 52 and ELEVATE UC 12 up to Wk 12, and from ELEVATE UC 52 and ELEVATE UC 40 JAPAN after Wk 12 up to Wk 52. BL, baseline; CI, confidence interval; CS, corticosteroid; LS, least squares; MMRM, mixed model for repeated measures; MMS, modified Mayo score; N, total number of patients per treatment group; n, number of patients with assessment at the specified visit; PBO, placebo; pt, patient; PRO2, patient-reported outcome 2; QD, once-daily; RBS, rectal bleeding subscore; SE, standard error; SFS, stool frequency subscore; UC, ulcerative colitis; Wk, Week. Conclusion: Etrasimod demonstrated robust efficacy in clinical, symptomatic and endoscopic endpoints and safety consistent with the overall population in pts with mildly to moderately active UC (MMS 4–6). Informationen zum Einsatz von KI : Pfizer's genAI tool MAIA assisted with 1st draft development; authors assume content responsibility. Publication History Article published online: 04 September 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,000 |
| Méta-épidémiologie (sens large) | 0,002 | 0,001 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,001 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».